Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.

Wu, Tzong-Yow; Chen, Pao-Yu; Wang, Jann-Tay; Liu, Wang-Da; Chen, Yee-Chun; Chang, Shan-Chwen

Wu, Tzong-Yow; Chen, Pao-Yu; Wang, Jann-Tay; Liu, Wang-Da; Chen, Yee-Chun; Chang, Shan-Chwen.

Affiliation

Wu TY; Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 100, Taiwan.
Chen PY; Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 100, Taiwan.
Wang JT; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Liu WD; Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 100, Taiwan.
Chen YC; National Institutes of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan.
Chang SC; Department of Internal Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.

J Antimicrob Chemother ; 79(5): 1196-1200, 2024 05 02.

Article in En | MEDLINE | ID: mdl-38538154

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Adenosine / Adenosine Monophosphate / Immunocompromised Host / Alanine / Drug Therapy, Combination / SARS-CoV-2 / COVID-19 Drug Treatment Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: J Antimicrob Chemother Year: 2024 Document type: Article Affiliation country: Taiwán Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google